tbuckley/cabot-search huggingface dataset:
mTOR Pathway Links Suppressed Autophagy to HDAC Inhibitor-Induced Apoptosis in Myeloid Leukemia,
Authors: Metodi V. Stankov, Kirsten Heitmann, Zhe Li, Basant Kumar Thakur, Diana Panayotova-Dimitrova, Jennifer Schöning, Jean-Pierre Bourquin, Tino Dittrich, Stephan Emmrich, Nora Schweitzer, Martin Leverkus, Dirk Reinhardt, Stuart H. Orkin, Georg M.N. Behrens, Jan-Henning Klusmann
Journal: Blood (2011)
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
Authors: Kiyotaka Yoh, Takashi Seto, Miyako Satouchi, Makoto Nishio, Noboru Yamamoto, Haruyasu Murakami, Naoyuki Nogami, Shingo Matsumoto, Takashi Kohno, Koji Tsuta, Katsuya Tsuchihara, Genichiro Ishii, Shogo Nomura, Akihiro Sato, Atsushi Ohtsu, Yuichiro Ohe, Koichi Goto
Journal: The Lancet Respiratory Medicine (2016)
Phase 1 Study of ABT-348, A Dual Aurora/VEGF-Receptor Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies.
Authors: Guillermo Garcia-Manero, Raoul Tibes, Yi-Lin Chiu, Hao Xiong, Qin Qin, Peter Ansell, Daniel H. Albert, Chris Tse, Brian Oliver, Karim Sajwani, Mark D. McKee, Justin L. Ricker, H. Jean Khoury
Journal: Blood (2012)
Associating the learning curve and tumor anatomical complexity with the margins, ischemia, and complications rate after robot-assisted partial nephrectomy
Authors: Yongpeng Xie, Xin Ma, Liangyou Gu, Hongzhao Li, Xiangjun Lv, Yu Gao, Yuanxin Yao, Luyao Chen, Yu Zhang, Xu Zhang
Journal: International Journal of Surgery (2016)
Inter-Rater Reliability of the 4Ts Scoring System for Diagnosing Heparin-Induced Thrombocytopenia in Critically Ill Patients.
Authors: Mark A. Crowther, Nicole Zytaruk, Katherine Krolicki, Suzanne Duchesne, Theodore E. Warkentin, Diane Heels-Ansdell, Jo-Ann Sheppard, Stephen Walter, Gordon Guyatt, Cook Deborah
Journal: Blood (2009)
Single ocular injection of a sustained-release anti -VEGF delivers 6 months pharmacokinetics and efficacy in a primate laser CNV model
Authors: Peter Adamson, Thomas Wilde, Eric Dobrzynski, Caroline Sychterz, Rodd Polsky, Edit Kurali, Richard Haworth, Chi-Man Tang, Justyna Korczynska, Fiona Cook, Irene Papanicolaou, Lemy Tsikna, Chris Roberts, Zoe Hughes-Thomas, James Walford, Daniel Gibson, John Warrack, Jos Smal, Ruud Verrijk, Paul E. Miller, T. Michael Nork, Jeffery Prusakiewicz, Timothy Streit, Steven Sorden, Craig Struble, Brian Christian, Ian R. Catchpole
Journal: Journal of Controlled Release (2016)

A potent anti-vascular endothelial growth factor (VEGF) biologic and a compatible delivery system were co-evaluated for protection against wet age-related macular degeneration (AMD) over a 6month period following a single intravitreal (IVT) injection. The anti-VEGF molecule is dimeric, containing two different anti-VEGF domain antibodies (dAb) attached to a human IgG1 Fc region: a dual dAb. The delivery system is based on microparticles of PolyActive™ hydrogel co-polymer. The molecule was evaluated both in vitro for potency against VEGF and in ocular VEGF-driven efficacy models in vivo. The dual dAb is highly potent, showing a lower IC
Support for the microgenderome invites enquiry into sex differences
Authors: Amy Wallis, Henry Butt, Michelle Ball, Donald P. Lewis, Dorothy Bruck
Journal: Gut Microbes (2016)

The microgenderome defines the interaction between microbiota, sex hormones and the immune system. Our recent research inferred support for the microgenderome by showing sex differences in microbiota-symptom associations in a clinical sample of patients with myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS). This addendum expands upon the sex-specific pattern of associations that were observed. Interpretations are hypothesized in relation to genera versus species-level analyses and D-lactate theory. Evidence of sex-differences invites future research to consider sex comparisons in microbial function even when microbial abundance is statistically similar. Pairing assessment of clinical symptoms with microbial culture, DNA sequencing and metabolomics methods will help advance our current understandings of the role of the microbiome in health and disease.
Identification of the Genomic Breakpoints at 1p36.3 and 3q21.3 in Five MDS/AML(M4) Patients with t(1;3)(p36;q21) Translocation. GATA2 Mutation May Be Involved in Leukemogenesis.
Authors: Phan Thi Xinh, Hoang Anh Vu, Fumitoshi Taketazu, Shin Fujisawa, Hideo Tanaka, Fumiharu Yagasaki, Atsushi Toyoda, Yoshiyuki Sakaki, Janet D. Rowley, Katsushi Tokunaga, Yuko Sato
Journal: Blood (2004)
Highlights in the Treatment of Lung Cancer
Authors: Martin J. Edelman
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
An Activating Mutation (Ser525Pro) within the Transactivation Domain of REL in Two Patients with Human B-Cell Lymphomas Enhances REL’s In Vitro Transforming Activity.
Authors: Heiko Trautmann, Daniel T. Starczynowski, Christiane Pott, Lana Harder, Norbert Arnold, Reiner Siebert, Michael Kneba, Thomas D. Gilmore
Journal: Blood (2005)
Trusts risk litigation payouts by not adopting full consent process, warns college
Authors: Clare Dyer
Journal: BMJ (2016)

NHS trusts risk a dramatic rise in litigation payouts unless they change the way they obtain patients’ consent to operations, the Royal College of Surgeons (RCS) has warned, after a landmark case in the UK Supreme Court.

The judgment last year in Montgomery v Lanarkshire Health Board requires doctors to explore the risks of proposed treatments and available alternatives much more thoroughly with patients.1 But the college fears that this message may not have fully filtered through, and it has issued new guidance to help surgeons adapt their processes.2

“The …
S-1 plus oxaliplatin compared with fluorouracil/leucovorin/oxaliplatin as neoadjuvant chemotherapy for locally advanced gastric carcinoma.
Authors: Jiren Yu, Yijun Wu, Yuan Gao, Qianyun Shen, Qing Zhang, Xiaosun Liu, Kankai Zhu
Journal: Journal of Clinical Oncology (2012)

147 Background: Perioperative chemotherapy could improve the prognosis compared with surgery alone. This study is to compare the efficacy and safety of S-1 and oxaliplatin (SOX) with fluorouracil, leucovorin and oxaliplatin (FOLFOX) as neoadjuvant chemotherapy for locally advanced gastric carcinoma. Methods: Patients with histologically confirmed locally advanced gastric carcinoma were enrolled and divided into two groups. Preoperative staging and response evaluation was achieved mainly by gastroscopy and abdominal computer tomography. Neoajuvant chemotherapy consisted of 2-6 cycles of S-1 80mg/m2 (2-week administration and 1-week rest) plus oxaliplatin 130mg/m2 on Day1 in SOX group, or 2 h infusion of 130mg/m2 oxaliplatin plus 2h infusion of 400 mg/m2 leucovorin, followed by infusion of 400 mg/m2 5-fluorouracil on Day 1 and 46 h 2.4 g/m2 bolus in FOLFOX group. The clinical response was evaluated after 2 cycles of chemotherapy, and surgery was attempted. Results: From 2009.9 to 2011.5, 88 patients were enrolled in this study(56 in SOX and 32 in FOLFOX). The clinical response rate was significant higher in the SOX compared with FOLFOX (54.7% vs. 31.2%, p=0.03). 68 patients received surgery(45 in SOX and 23 in FOLFOX), R0 resection rate was similar in both group (SOX: 93.3% vs. FOLFOX: 82.6%, p=0.22). Pathological complete response was observed in 3 patients in SOX group. All enrolled patients were evaluated for the adverse events (AE). The most common non-hematological AE was nausea (57.1% in SOX and 50% in FOLFOX) and vomiting (41.1% in SOX and 40.6% in FOLFOX). The major hematological AE included thrombocytopenia (37.5% in SOX and 21.9% in FOLFOX), neutropenia (33.9% in SOX and 53.1% in FOLFOX) and leukocytopenia (32.1% in SOX and 40.6% in FOLFOX). Conclusions: SOX had higher response rate and acceptable toxicity compared with FOLFOX as neoadjuvant chemotherapy.
Nanoparticles – a Novel Approach to Chronic Lymphocytic Leukemia Treatment?
Authors: Ida Franiak-Pietryga, Ewelina Ziolkowska, Barbara Ziemba, Dietmar Appelhans, Brigitte Voit, Joanna Gora-Tybor, Tadeusz Robak, Barbara Klajnert, Maria Bryszewska
Journal: Blood (2012)
BET Inhibitors Suppress ALDH Activity by Targeting <i>ALDH1A1</i> Super-Enhancer in Ovarian Cancer
Authors: Yuhki Yokoyama, Hengrui Zhu, Jeong Heon Lee, Andrew V. Kossenkov, Sherry Y. Wu, Jayamanna M. Wickramasinghe, Xiangfan Yin, Katherine C. Palozola, Alessandro Gardini, Louise C. Showe, Kenneth S. Zaret, Qin Liu, David Speicher, Jose R. Conejo-Garcia, James E. Bradner, Zhiguo Zhang, Anil K. Sood, Tamas Ordog, Benjamin G. Bitler, Rugang Zhang
Journal: Cancer Research (2016)

The emergence of tumor cells with certain stem-like characteristics, such as high aldehyde dehydrogenase (ALDH) activity due to ALDH1A1 expression, contributes to chemotherapy resistance and tumor relapse. However, clinically applicable inhibitors of ALDH activity have not been reported. There is evidence to suggest that epigenetic regulation of stem-related genes contributes to chemotherapy efficacy. Here, we show that bromodomain and extraterminal (BET) inhibitors suppress ALDH activity by abrogating BRD4-mediated ALDH1A1 expression through a super-enhancer element and its associated enhancer RNA. The clinically applicable small-molecule BET inhibitor JQ1 suppressed the outgrowth of cisplatin-treated ovarian cancer cells both in vitro and in vivo Combination of JQ1 and cisplatin improved the survival of ovarian cancer-bearing mice in an orthotopic model. These phenotypes correlate with inhibition of ALDH1A1 expression through a super-enhancer element and other stem-related genes in promoter regions bound by BRD4. Thus, targeting the BET protein BRD4 using clinically applicable small-molecule inhibitors, such as JQ1, is a promising strategy for targeting ALDH activity in epithelial ovarian cancer. Cancer Res; 76(21); 6320-30. ©2016 AACR.
Tracking T-cell immune reconstitution after TCRαβ/CD19-depleted hematopoietic cells transplantation in children
Authors: I V Zvyagin, I Z Mamedov, O V Tatarinova, E A Komech, E E Kurnikova, E V Boyakova, V Brilliantova, L N Shelikhova, D N Balashov, M Shugay, A L Sycheva, S A Kasatskaya, Y B Lebedev, A A Maschan, M A Maschan, D M Chudakov
Journal: Leukemia (2016)
Protein Tomography Analysis Shows That CD20 Molecules Bound by Different Type I and Type II Anti-CD20 Antibodies Are Organized in Different Protein Complexes.
Authors: Gerhard J Niederfellner, Annika Braennstroem, Frida Lindstrom, Magnus Jansson, Marika Lundin, Wolfgang Schaefer, Olaf Mundigl, Pablo Umana, Christian Klein
Journal: Blood (2009)
Atiprimod Inhibits the Growth of JAK2 Tyrosine Kinase Over-Expressing Cells “In Vitro” and “Ex Vivo”.
Authors: Roberto Nussenzveig, Taghi Manshouri, Hagop Kantarjian, Francis Giles, Jorge Cortes, Amos Gaikwad, Waldemar Priebe, Zeev Estrov, Srdan Verstovsek
Journal: Blood (2006)
The Type I Interferonopathies
Authors: Min Ae Lee-Kirsch
Journal: Annual Review of Medicine (2016)

Type I interferons (IFNs) play a central role in the immune defense against viral infections. Type I IFN activation is induced by pattern-recognition receptors of the innate immune system that sense pathogen-derived nucleic acids. Cellular responses to type I IFN signaling are orchestrated by a complex network of regulatory pathways that involve both the innate and adaptive immune system. The genetic and molecular dissection of rare Mendelian disorders associated with constitutive overproduction of type I IFN has provided unique insight into cell-intrinsic disease mechanisms that initiate and sustain autoinflammation and autoimmunity and that are caused by disturbances in the intracellular nucleic acid metabolism or in cytosolic nucleic acid-sensing pathways. Collectively, these findings have greatly advanced our understanding of mechanisms that protect the organism against inappropriate immune activation triggered by self nucleic acids while maintaining a prompt and efficient immune response to foreign nucleic acids derived from invading pathogens.
Defining the brain circuits involved in psychiatric disorders: IMI-NEWMEDS
Authors: Francesc Artigas, Esther Schenker, Pau Celada, Michael Spedding, Laia Lladó-Pelfort, Noemi Jurado, Mercedes Núñez, Noemi Santana, Eva Troyano-Rodriguez, Maurizio S. Riga, Hanna van den Munkhof, Anna Castañé, Hamdy Shaban, Thérèse M. Jay, Anushree Tripathi, Bill P. Godsil, Claude Sebban, Jean Mariani, Philippe Faure, Samir Takkilah, Zoe A. Hughes, Chester J. Siok, Mihaily Hajos, Karsten Wicke, Natalia Gass, Wolfgang Weber-Fahr, Alexander Sartorius, Robert Becker, Michael Didriksen, Jesper F. Bastlund, Mark Tricklebank, Céline Risterucci, Andreas Meyer-Lindenberg, Adam J. Schwarz
Journal: Nature Reviews Drug Discovery (2016)
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial
Authors: Joel W Neal, Suzanne E Dahlberg, Heather A Wakelee, Seena C Aisner, Michaela Bowden, Ying Huang, David P Carbone, Gregory J Gerstner, Rachel E Lerner, Jerome L Rubin, Taofeek K Owonikoko, Philip J Stella, Preston D Steen, Ahmed Ali Khalid, Suresh S Ramalingam
Journal: The Lancet Oncology (2016)
Autoimmune Cytopenias In Chronic Lymphocytic Leukemia: Prevalence, Clinical Correlations, and Prognostic Significance In a Large, Unselected Series of Patients From a Single Institution
Authors: Carol Moreno, Kate E Hodgson, Gerardo Ferrer, Montse Elena, Xavier Filella, Arturo Pereira, Tycho Baumann, Emili Montserrat
Journal: Blood (2010)
First European Chemotherapy Schedule for Elderly Patients with Acute Lymphoblastic Leukemia: Promising Remission Rate and Feasible Moderate Dose Intensity Consolidation
Authors: Nicola Goekbuget, Thibaut Leguay, Mathilde Hunault, Chadi Al-Nawakil, Patrice Chevallier, Herve Dombret, Gisela Fritsch, Albert Oriol, Josep Maria Ribera, Philippe Rousselot, Juan Manuel Sancho, Dieter Hoelzer
Journal: Blood (2008)
Orbital/Periorbital Plexiform Neurofibromas in Children with Neurofibromatosis Type 1
Authors: Robert A. Avery, James A. Katowitz, Michael J. Fisher, Gena Heidary, Eva Dombi, Roger J. Packer, Brigitte C. Widemann, Kelly A. Hutcheson, William P. Madigan, Robert Listernick, Grant T. Liu, Jerry E. Berland, Edmond J. FitzGibbon, Bruce R. Korf
Journal: Ophthalmology (2016)
Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
Authors: Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio, Albrecht Reichle, Carlos Graux, Christoph Faul, Helmut Diedrich, Max S. Topp, Monika Brüggemann, Heinz A. Horst, Julia Stieglmaier, Hendrik Wessels, Vincent Haddad, Gerhard Zugmaier, Dirk Nagorsen, Ralf C Bargou
Journal: Blood (2015)
African American Patients with Multiple Myeloma Have Prolonged Responses after Autologous Stem Cell Transplantation.
Authors: Santosh Saraf, Yi-Hsiang Chen, Lisa C. Dobogai, Yogen Saunthararajah, David Peace, Ronald Hoffman, Nadim Mahmud, Sandeep Chunduri, Damiano Rondelli
Journal: Blood (2005)
CELLULAR MECHANISMS OF PROTEIN METABOLISM IN THE NEPHRON
Authors: Yin Chen Lee
Journal: The Journal of Experimental Medicine (1954)

1. The cells of the proximal convolutions of the rat can be filled with fine droplets by the administration of certain amino acids in non-toxic dosage. 2. These minute droplets resemble in their Gram positivity and in their phospholipid and PNA content on biochemical analysis (3) the larger droplets that form in the cells of the proximal convolution during the absorption of certain proteins. 3. The positive or negative reaction to 3 specific histochemical procedures of the fine droplets forming after administration of 7 amino acids gave such a high positive correlation with theoretical assumption as to warrant the following inferences: (a) that the methods are specific under the conditions of the experiment; (b) that the droplets contain a higher concentration of the administered amino acid than the general cytoplasm of the cells which contain them. 4. The mitochondrial rodlets of epithelium of the proximal convolution contain sulfhydryl in high concentration, a finding which correlates well with their enzymatic activity.
Infusional Adriamycin Based Chemotherapy Significantly Improves the Survival of Human T-Cell Lymphotropic Virus-I Induced Acute Type Adult T-Cell Leukemia Lymphoma.
Authors: Daniel Efiom-Ekaha, Joseph Feldman, Susan Gottesman, Natalya Krichmar, Olugbenga Olowokure, Jasotha Sanmugaharajah, Iuliana Shapira, William B. Solomon, Emily Qian Chen
Journal: Blood (2005)
Unrelated Donor Peripheral Blood Stem Cell (PBSC) Transplantation Using Nonmyeloablative Conditioning and Mycophenolate Mofetil (MMF) TID Results in High Engraftment Rates.
Authors: Michael B. Maris, B. M. Sandmaier, B. Storer, J. Shizuru, D. Maloney, E. Agura, D. Niederwieser, M. Pulsipher, R. T. Maziarz, P. McSweeney, J. Wade, A. Langston, T. Chauncey, B. Bruno, A. Woolfrey, M.T. Little, K. Blume, R. Storb
Journal: Blood (2004)
Lymphodepletion Followed By Suicide-Gene-Transduced Donor Lymphocyte Infusion: A Strategy To Safely Enhance The Graft-Versus-Tumor Effect
Authors: Sebastien Maury, Michelle Rosenzwajg, Rabah Redjoul, Ambroise Marcais, Alienor Xhaard, Ludovic Cabanne, Mustapha Cherai, Felipe Suarez, Regis Peffault de Latour, Laetitia Gregoire, Karima Debbache, Claude Bernard, Jean-Louis Beaumont, Nabih Azar, Françoise roudot-Thoraval, Dominique Bories, JosÉ Cohen, Catherine Cordonnier, Francois Michel Lemoine, David Klatzmann
Journal: Blood (2013)
Phase 1/2a Study of ABT-263 in Relapsed or Refractory Lymphoid Malignancies.
Authors: Wyndham H Wilson, Owen A O'Connor, Myron S Czuczman, Ann LaCasce, John Gerecitano, John P. Leonard, Anil Tulpule, Hao Xiong, Yi-Lin Chiu, Todd Busman, Sari Enschede, Andrew Krivoshik, Rod Humerickhouse
Journal: Blood (2009)
Unusual Presentations of Lung Cancer
Authors: Carmen Iamandi, Anita Dietemann, Edouard Grosshans, Gabrielle Pauli, Elisabeth Quoix
Journal: Journal of Clinical Oncology (2002)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.23.4600 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12454120 Unusual Presentations of Lung Cancer Case 3. Paraneoplastic Digital Necrosis in a Patient With Small-Cell Lung Cancer Carmen IamandixCarmen IamandiSearch for articles by this author , Anita DietemannxAnita DietemannSearch for articles by this author , Edouard GrosshansxEdouard GrosshansSearch for articles by this author , Gabrielle PaulixGabrielle PauliSearch for articles by this author , Elisabeth QuoixxElisabeth QuoixSearch for articles by this author Show More University Hospital, Strasbourg, France https://doi.org/10.1200/JCO.2002.20.23.4600 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
The Vent-Like Homeobox Gene VENTX2 Is Expressed in Human Hematopoietic Progenitor Cells and Promotes Human Myeloid Development In Vitro and In Vivo.
Authors: Natalia Arseni, Farid Ahmed, Vijay P.S. Rawat, Timothy J. Sadlon, Wolfgang Hiddemann, Christian Buske, Michaela Feuring-Buske
Journal: Blood (2007)
ATPS-38ASSESSMENT OF OPTIMIZED THERAPEUTIC TERM WITH TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA
Authors: Soko Ikuta, Takashi Maruyama, Katsuya Maebayashi, Masayuki Nitta, Taiichi Saito, Manabu Tamura, Atsushi Fukui, Saori Okamoto, Hiroshi Iseki, Takakazu Kawamata, Yoshihiro Muragaki
Journal: Neuro-Oncology (2015)

BACKGROUND: Standard therapeutics for glioblastoma is tumor removal followed by radiotherapy and chemotherapy with temozolomide (TMZ). Additional six cycles of TMZ is usually given, but it is unclear whether six cycles is sufficient to reduce recurrence. In our series, 25% of patients with GBM treated with TMZ lived more than one year without recurrence, and most of them received 12 cycles or more of TMZ chemotherapy. We retrospectively assessed the efficacy of long term TMZ in these case series. METHODS: Patients with newly diagnosed GBM, treated with 12 cycles or more TMZ after concomitant radiotherapy without relapse, were consecutively sampled at our institution from 2006 to 2014. The patents were categorized into 4 groups according to number of TMZ chemotherapy A) 12 cycles, B) 24 cycles, C) more than 24 cycles until relapse, D) beyond 12 cycles (included B, C). Progression free survival (PFS) after initial surgery, and PFS after the date of the final chemotherapy were analyzed by Kaplan-Meier estimate. RESULTS: A total of 52 patients met the criteria. Groups A, B, C and D included 12, 14, 12 and 40 patients, respectively. Each group had similar backgrounds. Median survival time (MST) and PFS of all patients was 6.8 and 4.3 years, respectively. There were no significant differences in PFS after the initial surgery between group A and B (p = 0.5889) and between C and D (p = 0.9243). Also, PFS after the final date of chemotherapy between group A and D (p = 0.5778), C and D (p = 0.8498) showed no difference, suggesting no benefit of more than 12 cycles of chemotherapy. CONCLUSION: This study suggested that patients with newly diagnosed GBM who are able to continue 12 cycles of TMZ chemotherapy can expect 6.3 years of OS and 4.3 years of PFS. More than 12 cycles of chemotherapy showed no additional survival benefit.
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP)
Authors: Michael D Tarantino, James B. Bussel, Victor S. Blanchette, Jenny Despotovic, Carolyn Bennett, Ashok Raj, Bronwyn Williams, Donald Beam, Jaime Morales, Melissa J. Rose, Nancy Carpenter, Kun Nie, Melissa Eisen
Journal: Blood (2015)
A New Molecular and Clinical Prognostic Score for Risk Stratification in CN-AML.
Authors: Friederike Schneider, Annika Dufour, Tobias Benthaus, Stephanie Schneider, Gudrun Mellert, Evelyn Zellmeier, Stefan K Bohlander, Michael Unterhalt, Michaela Feuring-Buske, Christian Buske, Jan Braess, Maria Cristina Sauerland, Achim Heinecke, Wolfgang Berdel, Thomas Buechner, Bernhard Wörmann, Wolfgang Hiddemann, Karsten Spiekermann, Eva Hoster
Journal: Blood (2009)
Methylen Blue Photoinactivated Plasma vs Fresh Frozen Plasma in Thrombotic Thrombocytopenic Purpura Treatment: A Multicentric Prospective Cohort Study.
Authors: Alberto Alvarez-Larrán, Julio Del Río-Garma, Javier de la Rubia, Concepción Zamora, Antonio Galmés, Consuelo Ramírez, Pilar Rodríguez-Vicente, Clara Martínez, Adrian Alegre, Aurora Viejo, Cristina Arbona, Alfons Serrano, María Dolors Castellá, Mercedes Corral, Francisco Peña, Arturo Pereira
Journal: Blood (2007)